Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Objective: Recent reports have described cases of telithromycin-related hepatotoxicity. The objective of this study is to quantify the effect of telithromycin use on the risk of hepatotoxicity.
Methods: We conducted a spontaneous-report case-control study of hepatotoxicity in telithromycin recipients using reports from the US FDA Adverse Event Reporting System. Reports from between 1 January 2005 and 30 June 2005 were examined. Cases included reports of patients with abnormal liver function tests, hepatocellular damage and hepatic impairment, while patients with reported conditions with similar reporting probabilities were considered as controls. The primary outcome measure of the analysis was the reporting odds ratio (ROR) evaluating the a priori hypothesis that telithromycin use confers an elevated risk of hepatotoxicity relative to other agents.
Results: A total of 2219 cases and 20,667 controls were identified. We estimated an ROR for hepatotoxicity associated with telithromycin compared with other agents of 1.82 (95% CI 1.12, 2.96) after controlling for age and gender, approximating an 82% excess risk in users of telithromycin relative to users of other agents.
Conclusions: This analysis is the first to specifically quantify the effect of telithromycin on the risk of hepatotoxicity. Telithromycin use may increase the risk of hepatotoxicity by >80%. Biases inherent in spontaneous reports include under-reporting of events and differential or time-varying reporting due to enhanced clinician awareness. Future studies should employ alternative data sources because of the inherent limitations of passive surveillance systems.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2165/00002018-200730080-00006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Green approach to the synthesis of 3,4-dihydropyrimidinone with zirconyl oxychloride as catalyst: In vitro antidiabetic evaluation, molecular dynamic simulation, density functional theory and toxicity assessment.
Bioorg Chem
September 2025
Post Graduate and Research Department of Botany, A.V.V.M. Sri Pushpam College (Affiliated to Bharathidasan University), Poondi 613 503, Thanjavur, India. Electronic address:
The research employed zirconyl oxychloride as a catalyst in a reaction involving pyrazole aldehyde, (thio)urea, and acetyl acetone to establish an aqueous approach for synthesizing 3,4-dihydropyrimidinone derivatives (compounds 4a-j) with potential claims as antidiabetic agents. FT-IR, HR-MS, H NMR and C NMR were employed to analyze the synthesized compounds. The HOMO-LUMO analysis was performed to evaluate the stability of the synthesized derivatives.
View Article and Find Full Text PDFA multi-dimensional computational framework of drug-induced hepatotoxicity: integrating molecular structure features with disease pathogenesis.
Brief Bioinform
August 2025
College of Pharmacy, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing 400016, P. R. China.
Drug-induced hepatotoxicity (DIH), characterized by diverse phenotypes and complex mechanisms, remains a critical challenge in drug discovery. To systematically decode this diversity and complexity, we propose a multi-dimensional computational framework integrating molecular structure analysis with disease pathogenesis exploration, focusing on drug-induced intrahepatic cholestasis (DIIC) as a representative DIH subtype. First, a graph-based modularity maximization algorithm identified DIIC risk genes, forming a DIIC module and eight disease pathogenesis clusters.
View Article and Find Full Text PDFCase Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer.
Front Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDFIdiosyncratic Drug-Induced Liver Injury in a Patient With Metastatic Melanoma.
Cureus
August 2025
Internal Medicine, Hospital Corporation of America (HCA) Florida Westside Hospital, Plantation, USA.
This is a case of drug-induced liver injury (DILI) in a 75-year-old male patient with a history of metastatic melanoma, who initially presented with a syncopal episode causing a fall. Following stabilization in the emergency department (ED), the patient was found to have bilateral subdural hematomas, and later an MRI showed evidence of metastatic lesions in the brain with hemorrhagic conversion. These findings led to a prolonged inpatient stay in the intensive care unit and eventual development of pneumonitis, which was subsequently treated with hepatotoxic antibiotics despite initial labs showing mildly elevated liver enzymes.
View Article and Find Full Text PDFFactors influencing hematological toxicity and adverse effects of perioperative hyperthermic intraperitoneal vs intraperitoneal chemotherapy in gastrointestinal cancer.
Open Med (Wars)
August 2025
Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing, 100053, P. R. China.
Background: Intraperitoneal (IP) chemotherapy (IPC), including hyperthermic intraperitoneal chemotherapy (HIPEC), has emerged as a promising approach to control peritoneal metastases in gastrointestinal (GI) cancers. However, the safety profile and toxicity spectrum of IPC remain incompletely understood. This study aimed to evaluate the incidence of hematologic and biochemical adverse reactions following surgery with or without IPC and to compare the toxicity profiles of normothermic IPC and HIPEC.
View Article and Find Full Text PDF